- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03105999
Observational Study On The Characterization Of 24-Hour Symptoms In Patients With COPD (STORICO)
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Ancona, Italia, 60127
- Ospedale INRCA - Clinica Medicina Interna e Geriatria
-
Asti, Italia, 14100
- Ospedale Cardinal G.Massaia - Pneumologia
-
Avellino, Italia, 83100
- A.O. San G.Moscati - U.O. Pneumologia
-
Bari, Italia, 70124
- Policlinico Consorziale - U.O. M.A.R.
-
Benevento, Italia, 82100
- A.O. G.Rummo - U.O.C. Pneumologia
-
Bergamo, Italia, 24125
- Humanitas Gavazzeni - Pneumologia
-
Bologna, Italia, 40185
- A.O.U. Policlinico S.Orsola Malpighi - Pneumologia
-
Catanzaro, Italia, 88100
- Policlinico Universitario Mater Domini - U.O.C. Malattie Apparato Respiratorio
-
Firenze, Italia, 50125
- Ospedale Piero Palagi - Fisiopatologia Respiratoria e Riabilitazione Respiratoria
-
Foggia, Italia, 71122
- Ospedale D'Avanzo - MAR 4 Univ.
-
Messina, Italia, 98158
- Ospedale Papardo - Malattie Apparato Respiratorio
-
Milano, Italia, 20153
- A.O. San Carlo Borromeo - Pneumologia
-
Milano, Italia, 20162
- Ospedale Niguarda - Pneumologia
-
Modena, Italia, 41124
- A.O.U. Policlinico - Clinica Malattie Apparato Respiratorio
-
Napoli, Italia, 80138
- A.O.U. Seconda Università Napoli - UOSD Serv.Prevenz.Mal.Broncopolm.
-
Nuoro, Italia
- Ospedale Zonchello - U.O.C. Pneumologia
-
Palermo, Italia, 90146
- Consiglio Nazionale delle Ricerche - Istituto di Biomedicina ed Immunologia Molecolare
-
Pisa, Italia, 56124
- Fondazione Toscana G. Monasterio - U.O.C. Pneumologia
-
Roma, Italia, 00135
- Ospedale San Filippo Neri - U.O.C. Pneumologia
-
Roma, Italia, 00157
- Ospedale Sandro Pertini - S.C. Pneumologia
-
Roma, Italia, 00184
- Ospedale San Giovanni Addolorata - U.O.C. Malattie Apparato Respiratorio
-
Roma, Italia, 00189
- Azienda Ospedaliera Sant'Andrea - U.O.C. Pneumologia
-
Salerno, Italia, 84131
- A.O.U. San Giovanni di Dio Ruggi d'Aragona - Pneumologia universitaria
-
Teramo, Italia, 64100
- Ospedale Mazzini - Malattie Apparato Respiratorio
-
Terni, Italia, 05100
- Azienda Unità Sanitaria Locale Umbria n.2 - U.O. Pneumologia Terr.
-
Torino, Italia, 10141
- Ospedale Martini - Pneumologia
-
-
Bari
-
Acquaviva delle Fonti, Bari, Italia, 70021
- Ospedale Ecclesiastico Miulli - Fisiopatologia Respiratoria
-
-
Brescia
-
Chiari, Brescia, Italia, 25032
- A.O. Mellino Mellini - U.O. Fisiopatologia Respiratoria
-
-
Caserta
-
Mondragone, Caserta, Italia, 81034
- Clinica Padre Pio - Medicina
-
-
Como
-
Menaggio, Como, Italia, 22017
- Ospedale Erba Renaldi - Medicina Interna
-
-
Genova
-
Sestri Levante, Genova, Italia, 16039
- Ospedale di Sestri Levante - Pneumologia
-
-
Lecco
-
Casatenovo, Lecco, Italia, 23880
- I.N.R.C.A. Centro per le Broncopneumopatie - Pneumologia Riabilitativa
-
-
Milano
-
Abbiategrasso, Milano, Italia, 20081
- Ospedale C. Cantù - Pneumologia
-
-
Monza E Brianza
-
Monza, Monza E Brianza, Italia, 20900
- Ospedale San Gerardo - Clinica Pneumologica
-
-
Napoli
-
Casoria, Napoli, Italia, 80026
- Ospedale S. Maria della Pietà Camilliani - Pneumologia e Fisiologia Respiratoria
-
Pollena Trocchia, Napoli, Italia, 80040
- Ospedale Apicella - U.O.C. Pneumologia
-
-
Ragusa
-
Modica, Ragusa, Italia, 97015
- Ospedale Maggiore - U.O. Medicina
-
-
Torino
-
Orbassano, Torino, Italia, 10043
- A.O.U. San Luigi Gonzaga - Malattie Apparato Respiratorio 1
-
-
Treviso
-
Vittorio Veneto, Treviso, Italia, 31029
- Ospedale Civile - Pneumologia
-
-
Venezia
-
Dolo, Venezia, Italia
- Ospedale di Dolo - U.O.C. Pneumologia
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Male and female outpatients aged ≥ 50
- Diagnosis of stable COPD at least 12 months before the enrolment according to the GOLD 2014 criteria (stages A to D)
- Current smokers or ex-smokers with a smoking history of ≥ 10 pack-years (e.g. 10 pack years = 1 pack /day x 10 years, or ½ pack/day x 20 years. An ex-smoker will be defined as a subject who has not smoked for ≥6 months at baseline)
- Patients without any exacerbation at the baseline (enrolment visit) and in the last month prior to the enrolment visit
- Patients must be able and willing to read and comprehend written instructions, and comprehend and complete the questionnaires required by the protocol
- Patients who signed, after explanation, a written informed consent and privacy form, to confirm they understood the purpose of the study, and the procedure required in the study, and that they are willing to participate in the study.
Exclusion Criteria:
- Patients participating in a clinical trial at enrolment
- Patients who had changed active, dosage or frequency of administration of the maintenance therapy of COPD treatment regimen in the last 3 months prior to the enrolment visit (baseline)
- Patients with a previous diagnosis of asthma, sleep apnea syndrome or other chronic respiratory disease different from COPD or other relevant medical conditions (on clinician's opinion) that will reduce the life expectancy of less than 3 years (Charlson index not including COPD >3)
- Patients under long-term oxygen therapy
Study exit criteria:
- Withdraw of informed consent to participate in the study
- Diagnosis of asthma, sleep apnea syndrome or other chronic respiratory disease different from COPD
- Death
- Inclusion in a clinical trial
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Frequency of early-morning, day- and night-time COPD symptoms according to phenotypes in a cohort of Italian patients with stable COPD. Symptoms will be evaluated by means of the Night-Time, Morning and Day-Time symptoms of COPD questionnaire.
Periodo de tiempo: At baseline
|
The frequency of early-morning, day and night-time symptoms at enrolment will be assessed based on the questions of the "Night-time, Morning and Day-time Symptoms of COPD questionnaire". It will be calculated within each class of phenotype as the ratio between the number of patients with at least 1 (early-morning, day and night-time) symptom in the week before enrolment and the total number of evaluable patients in the class. Three proportions will be calculated (for early-morning, day and night-time). The frequency of early-morning, day and night-time symptoms severity will be described too: for this reason, the proportion of mild, moderate, severe and very severe early-morning, day- and night-time symptoms in the week before enrollment will be provided. The frequency of specific COPD symptoms (breathlessness, coughing, bringing up phlegm or mucus, wheezing, chest tightness, chest congestion) will be also provided according to phenotypes. |
At baseline
|
12-month frequency and change from baseline of early-morning, day- and night-time COPD symptoms according to phenotypes measured at enrolment. Symptoms will be evaluated by means of the Night-Time, Morning and Day-Time symptoms of COPD questionnaire.
Periodo de tiempo: 6 and 12 months
|
Phenotypes will be defined as per clinician judgment at enrollment. The proportion of patients changing phenotype during one-year observation provided. Within each class, the frequency of early-morning, day and night-time symptoms at each follow up visit will be calculated as the ratio between the number of patients with at least 1 symptom in the week preceding the follow up visit and the total number of evaluable patients in the class of phenotype with available "Night-time, Morning and Day-time Symptoms of COPD questionnaire" (COPD questionnaire) at follow up visit. For each patient the number of early-morning, day- and night-time symptom at each study visit together with the variation between visits will be calculated separately in the groups of patients according to baseline phenotype. The variation will be calculated as the difference between the number of symptoms at 12- (6-) month follow up and at baseline and between the number of symptoms at 12- and at 6-month follow up. |
6 and 12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Association between COPD symptoms frequency at enrolment and outcomes: • dyspnea level • disease severity (stages A to D GOLD 2014 criteria) • quality of life • physical activity • quality of sleep • exacerbations • depression and anxiety
Periodo de tiempo: At baseline
|
The association at enrolment will be evaluated by calculating the frequency of symptoms in the groups of patients according to disease severity (A, B, C, D in GOLD 2014 guideline). Frequency of symptoms will be provided according to number of exacerbations in the year before baseline (0-1 vs ≥2) and to severity of exacerbations in the year before. Chi-squared tests (or Fisher exact tests if appropriate) will be provided too. The descriptive statistics of dyspnea level (mMRC score), quality of life (SGRQ symptoms, activity and impacts on daily life scores and total score), physical activity (IPAQ walking, moderate-intensity, vigorous-intensity activity and total scores), quality of sleep (CASIS total score), level of depression and anxiety (HADS anxiety, depression and total score) at enrollment in patients with vs without at least one symptom will be provided; the association between symptoms and outcomes will be evaluated by means of student T-test. |
At baseline
|
12-month variation of the following outcomes according to phenotypes measured at enrolment: • dyspnea level • quality of life • physical activity • quality of sleep • frequency and severity of exacerbations • level of depression and anxiety
Periodo de tiempo: 6 and 12 months
|
At each follow up visit the following outcomes will be described and the variation (i.e. the difference) between each follow-up visit and since enrolment visit will be calculated by patient: dyspnea level (mMRC score), quality of life (SGRQ symptoms, activity and impacts on daily life scores and total score), physical activity (IPAQ walking, moderate-intensity, vigorous-intensity activity and total scores), quality of sleep (CASIS total score), level of depression and anxiety (HADS anxiety, depression and total score), number of exacerbations and of severe exacerbations.
Such differences will be summarized by means of descriptive statistics globally and stratified by phenotype assessed at enrollment.
|
6 and 12 months
|
Healthcare resources utilization in a cohort of Italian patients with COPD during 12-month observation, globally and by phenotypes
Periodo de tiempo: 6 and 12 months
|
The healthcare resources consumption will take into consideration the following events related both to management of COPD and to COPD exacerbations: inpatients and outpatients hospitalization, accesses to emergency department, GP and outpatient visits, laboratory tests, spirometry, pharmacological (LABA, LAMA, SABA, SAMA, etc.) and non-pharmacological therapies (rehabilitation) occurred/administered during study period. Medications for adverse events will be considered too. The annual direct healthcare resource consumption will be provided by means of descriptive statistics of the variables mentioned above. Analyses will be performed on the whole sample and stratified by phenotype. |
6 and 12 months
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011 Feb;37(2):264-72. doi: 10.1183/09031936.00051110. Epub 2010 Nov 29.
- Miravitlles M, Worth H, Soler Cataluna JJ, Price D, De Benedetto F, Roche N, Godtfredsen NS, van der Molen T, Lofdahl CG, Padulles L, Ribera A. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014 Oct 21;15(1):122. doi: 10.1186/s12931-014-0122-1.
- Incalzi RA, Blasi F, Canonica GW, Foschino MP, Prediletto R, Simoni L, Ori A, Giovannetti C, Barsanti S, Scichilone N. The Prescribing Practice for COPD: Relationship to Circadian Rhythm, Disease Severity, and Clinical Phenotype in the STORICO Observational Study. Adv Ther. 2022 Dec;39(12):5582-5589. doi: 10.1007/s12325-022-02331-x. Epub 2022 Oct 11.
- Blasi F, Antonelli Incalzi R, Canonica GW, Schino P, Cuttitta G, Zullo A, Ori A, Scichilone N; STORICO study group. Clinical Evolution and Quality of Life in Clinically Based COPD Chronic Bronchitic and Emphysematous Phenotypes: Results from the 1-Year Follow-Up of the STORICO Italian Observational Study. Int J Chron Obstruct Pulmon Dis. 2021 Jul 21;16:2133-2148. doi: 10.2147/COPD.S310428. eCollection 2021.
- Antonelli Incalzi R, Canonica GW, Scichilone N, Rizzoli S, Simoni L, Blasi F; STORICO study group. The COPD multi-dimensional phenotype: A new classification from the STORICO Italian observational study. PLoS One. 2019 Sep 13;14(9):e0221889. doi: 10.1371/journal.pone.0221889. eCollection 2019.
- Canonica GW, Blasi F, Scichilone N, Simoni L, Zullo A, Giovannetti C, Briguglio C, Barsanti S, Antonelli Incalzi R; STORICO study group. Characterization of circadian COPD symptoms by phenotype: Methodology of the STORICO observational study. Eur J Intern Med. 2017 Sep;43:62-68. doi: 10.1016/j.ejim.2017.05.021. Epub 2017 May 31.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- GUID/15/COPD/001
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .